Advisory Board

Professor Weian Zhao

Weian Zhao, Ph.D. is Assistant Professor, Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center, Department of Biomedical Engineering, Department of Pharmaceutical Sciences, University of California, Irvine. He is also Editorial Board Member of Stem Cells International, Nanotechnology, and Interface Focus.
 
Weian’s research aims to understand and ultimately control the fate of the transplanted stem cells in the body (i.e. where they go and what they do), which will lead to effective and safe clinical medicine. He studies the biological, therapeutic, and detrimental functions of transplanted stem cells in vivo, which will eventually allow us to better utilize them to treat a variety of diseases including cancer and stroke. Furthermore, he is developing bioengineered tools including microfluidics, nanoparticles, and aptamers to tackle unmet challenges in disease diagnosis and global health.
 
His papers include Paper-Based Bioassays Using Gold Nanoparticle Colorimetric Probes, Design of Gold Nanoparticle-Based Colorimetric Biosensing Assays, DNA Aptamer Folding on Gold Nanoparticles: From Colloid Chemistry to Biosensors, Rolling Circle Amplification: Applications in Nanotechnology and Biodetection with Functional Nucleic Acids, DNA Polymerization on Gold Nanoparticles through Rolling Circle Amplification: Towards Novel Scaffolds for Three-Dimensional Periodic Nanoassemblies, and Highly Stabilized Nucleotide-Capped Small Gold Nanoparticles with Tunable Size.
 
Weian earned his B.S. in Chemistry at Shandong University in 2000. He earned his M.S. in Chemistry at Shandong University in 2003. He earned his Ph.D. in Chemistry at McMaster University in 2008.
 
Read Stem cell researcher Weian Zhao tapped for prestigious TR35 list, Jellyfish inspire scientists to invent a device that can detect, capture and release rare cancer cells, and Bringing passion to medical science. View his Facebook page. Read his Google+ profile and his LinkedIn profile. Follow his Twitter feed.